RBM47: A Drug Target / Disease Biomarker (G54502)

Target Name: RBM47

NCBI ID: G54502

RBM47

RBM47: A Drug Target / Disease Biomarker

RNA-Binding Protein 4.7 (RBM4.7) is a protein that is expressed in various tissues and cells in the human body. It plays a crucial role in the regulation of gene expression and has been associated with various diseases, including cancer. Therefore, RBM4.7 has been considered as a potential drug target or biomarker.

RBM4.7 is a 22-kDa protein that is expressed in various tissues, including muscle, heart, liver, and brain. It is a member of the RNA-binding protein family 4.7, which includes other proteins such as RBM4.1, RBM4.2, RBM4.3, RBM4.6, and RBM4.8. These proteins share a conserved N-terminal region and a conserved N-terminal domain that is responsible for their unique structure and function.

RBM4.7 is involved in the regulation of gene expression by binding to specific DNA sequences. It has been shown that RBM4.7 can interact with various DNA-binding proteins, including histone modifications, non-coding RNAs, and coding RNAs. RBM4.7 has been shown to play a role in the regulation of cell proliferation, apoptosis, and autophagy.

One of the most significant findings related to RBM4.7 is its involvement in the regulation of cancer cell growth. Several studies have shown that RBM4.7 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has been shown to promote the growth and survival of cancer cells, and may contribute to their metastasis. Therefore, RBM4.7 has been identified as a potential drug target or biomarker for cancer treatment.

Another potential application of RBM4.7 is its role in the regulation of neurodegenerative diseases. RBM4.7 has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of pain perception. Several studies have shown that RBM4.7 is expressed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, RBM4.7 may be a promising biomarker or drug target for neurodegenerative diseases.

In addition to its potential applications in cancer and neurodegenerative diseases, RBM4.7 has also been shown to be involved in the regulation of stem cell biology. RBM4.7 has been shown to play a role in the regulation of stem cell self-renewal and differentiation. Therefore, RBM4.7 may be a potential drug target or biomarker for stem cell biology.

The structure and function of RBM4.7 are also of interest in the study of RNA-binding proteins. RBM4.7 has a conserved N-terminal region that is similar to other RNA-binding proteins, and it can interact with various DNA-binding proteins. This suggests that RBM4.7 may be a member of a subclass of RNA-binding proteins that are involved in the regulation of gene expression.

In conclusion, RBM4.7 is a protein that has been shown to be involved in the regulation of gene expression and has been associated with various diseases, including cancer, neurodegenerative diseases, and stem cell biology. Therefore, RBM4.7 has potential as a drug target or biomarker and is a promising area of research in the field of RNA-binding proteins.

Protein Name: RNA Binding Motif Protein 47

Functions: Single-stranded RNA-binding protein that functions in a variety of RNA processes, including alternative splicing, RNA stabilization, and RNA editing (PubMed:24038582, PubMed:24916387, PubMed:27050523, PubMed:30844405, PubMed:31358901, PubMed:34160127). Functions as an enzyme-substrate adapter for the cytidine deaminase APOBEC1. With APOBEC1 forms an mRNA editing complex involved into cytidine to uridine editing of a variety of mRNA molecules (PubMed:24038582, PubMed:24916387, PubMed:30844405). Through the binding of their 3'UTR, also stabilizes a variety of mRNAs and regulates the expression of genes such as the interferon alpha/beta receptor and interleukin-10 (PubMed:34160127). Also involved in the alternative splicing of several genes including TJP1. Binds the pre-mRNA (U)GCAUG consensus sequences in downstream intronic regions of alternative exons, regulating their exclusion and inclusion into mRNAs (PubMed:31358901, PubMed:27050523). Independently of its RNA-binding activity, could negatively regulate MAVS by promoting its lysosomal degradation (By similarity)

The "RBM47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets